<DOC>
	<DOCNO>NCT02543749</DOCNO>
	<brief_summary>The aim phase I/II trial induction anti leukemic T cell immunity clinical situation `` minimal residual disease '' . This might strategy immunologically eradicate residual leukemia cell . Patients include chronic phase bcr/abl+ CML ( chronic myeloid leukemia ) patient stable cytogenetic and/or molecular remission . These patient include : 1. achieve CMR ( complete molecular response ) 2. achieve bcr/abl &lt; 10 % qPCR ( quantitative polymerase chain reaction ) ( =MCyR ) ( Major cytogenic Response ) , less CCyR ( complete cytogenic Response ) . Autologous DC ( Dendritic cell ) , generate GMP ( Good manufacturing condition ) condition , use vaccine . These DC constitutively express putative tumor antigen . In order ensure sufficient presentation distinct CML-related antigen , particularly good responder TKIs , DC additionally pulse peptide bcr/abl , WT-1 ( Wilms Tumor Protein ) proteinase-3 . Monitoring T cell reactivity peptides serve surrogate marker anti leukemic immunity induce vaccine . Vaccination perform 10^7 DC i.d . ( intra dermal ) week 1 , 3 , 5 , 8 , 11 , 14 , 17 , 20 , 23 26 . KLH ( keyhole limpet hemocyanin ) use adjuvant vaccine preparation week 3 , 5 8 ( 11 ) .</brief_summary>
	<brief_title>DC Vaccination CML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Patients bcr/ablpositive CML stable cytogenetic / molecular remission least 18 month therapy tyrosine kinase Inhibitors ( TKI ) . The following group patient include : complete cytogenetic remission ( CCyR ) , stable detection bcr/abltranscript qPCR ( least two different time point period least 6 month ) . A stable molecular remission assume , difference qPCR value exceed factor 5 ( &lt; 0,5log ) . No CCyR , qPCR bcr/abl transcript &lt; 10 % ( = MCyR ( Major cytogenetic Response ) ) least 24 month 2nd generation TKI therapy . 2 . Treatment TKI inhibitor additional anti leukemic drug exclusion criterion . 3 . Age 1880 year 4 . Performance status 0 1 accord WHO index Karnofsky index &gt; 70 % 5 . Life expectancy &gt; 18 month 6 . Hematological function least partially conserve ( platelet count &gt; 50.000/ μl , Hb &gt; 8g/dl ) 7. write informed consent 8 . No breast feed 9. childbearing potential , negative pregnancy test ( serum/urine ß HCG ( human chorionic gonadotropin ) ) willingness use highly effective contraceptive method ( Pearl Index &lt; 1 , e.g . : birth control pill , loop , hormone implant , transdermal hormone patch , combination two barrier method [ condom vaginal diaphragm ] sterilisation sexual abstinence ) study duration thereafter long treatment antileukemic drug 1 . Clinically relevant autoimmune disorder 2 . Immunodeficiency syndromes 3 . Known allergy GMCSF ( granulocyte macrophage colonystimulating factor ) , TNFα ( Tumor necrosis factor Alpha ) , IL4 ( interleukine 4 ) KLH ( keyhole limpet hemocyanin ) 4 . Pregnancy ( absence confirm serum/urine ßHCG ) breastfeed 5 . Women childbearing age without highly effective contraception 6 . Active infectious disease require treatment 7 . Continuous therapy corticosteroid immunosuppressive drug 8 . Severe psychiatric disorder 9 . Organ dysfunction : Thrombin Time / Partial Thromboplastin Time &gt; 1,5 x upper normal limit creatinine &gt; 2,0 mg/ml Bilirubin &gt; 3,0 mg/ml , ALAT/ASAT ( Alanine aminotransferase/ aspartate aminotransferase ) &gt; 3x upper normal limit pulmonary disfunction ( dyspnea rest minimal exertion ) clinically relevant coronary heart disease ventricular arrhythmia , congestive heart failure &gt; grade II NYHA ( New York Heart Association ) 10 . Persons detain officially legally official institute 11 . Subjects concern compliance protocol procedures 12 . Present History substance abuse ( drug alcohol ) factor ( e.g. , serious psychiatric condition ) could limit subject 's ability comply study procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>CML</keyword>
	<keyword>DC vaccine</keyword>
</DOC>